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OBJECTIVES: To evaluate the cost of anemia management according to hemoglo-
bin level variability in hemodialysis (HD) patients.METHODS:Thiswas a retrospec-
tive study based on computerized medical files, (Hemodial® software database),
which included 636 HD patients in 5 dialysis centers in 2009. Patients were evalu-
able if they were regularly hemodialyzed, had at least one Hb recorded per month
and were monitored for at least 4 months. “Annual Hb values” were categorized
according to theirmonthlymeanHb (Ideal [10Hb 12 g/dL; n119]; High [Hb12
g/dL; n61] and Low [Hb  10 g/dL; n18] if 75% of time in respective category,
otherwise categorized in Fluctuating; n438). RESULTS: Out of 636 evaluable pa-
tients (mean age, 67 y; male, 59.4%) underwent 144 HD sessions (median); 16.8%
were new dialysis patients. The cost of anemiamanagement wasmainly related to
erythropoiesis-stimulating agents (68% of total cost for Low category and approx-
imately 90% for other categories). Adjusted predictive factors for higher costs of
anemia management (p0.0001) were: dialysis center (from 2518 to 5617€), age
(4911€  55 y vs. 5378€ 65–75 y), female gender (4911€ vs. 4398€ for male), serum
ferritin (5102€ for 200–500 g/mL vs. 4646€ for 500 g/mL) and dialysis vintage
(4911€ if  2 y vs. 2952€ if 4–6 y). The cost for patients in the Low Hb category (13
005€) was significantly higher compared to the others categories: Ideal (5034€),
Fluctuating (4911€) and High (2418€). CONCLUSIONS: Predictive of higher costs of
anemiamanagement in HD patients were the dialysis center, Low Hb category and
patients starting dialysis. Different treatment strategies led to acceptable Hb levels
but showed substantially different costs.
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A MANAGED CARE COST-OFFSET MODEL FOR FERRIC CITRATE, AN
EXPERIMENTAL PHOSPHATE BINDER THAT CAN REDUCE THE USE OF
ERYTHROPOIESIS-STIMULATING AGENTS AND INTRAVENOUS IRON IN
HEMODIALYSIS PATIENTS WITH HYPERPHOSPHATEMIA
Mutell R, Rubin JL, Bond TC, Mayne T
DaVita Clinical Research, Minneapolis, MN, USA
OBJECTIVES: According to 2009 figures from the US Renal Data System, 17% of all
patients received their first dialysis with private insurance coverage. Ferric citrate
(FC) is a phosphate binder (PB) in clinical development for the treatment of hyper-
phosphatemia in ESRD patients. Patients receiving FC in clinical studies experi-
enced reductions in serum phosphorus, and increases in serum ferritin and satu-
rated transferrin (TSAT). In an observational study analyzing data of a large dialysis
provider, similar increases in ferritin and TSAT in patients with stable hemoglobin
were associated with reduced doses of intravenous (IV) iron and erythropoiesis-
stimulating agents (ESAs) such as epoetin alfa. Reduced IV iron and ESA use could
lower costs of ESRD treatment for insurers.METHODS:We created amanaged care
cost-offset model that considered annual treatment costs of ESRD patients pre-
scribed FC versus alternative PBs. The model assumed similar efficacy and cost
neutrality between FC and other PBs. Baseline input values were derived from
published sources as well as a database analysis from a large US dialysis provider.
Monte Carlo simulations were performed using varying model inputs such as the
number of patients insured, proportion of ESRD patients on PBs, number of dialysis
sessions, estimated cost for dialysis, and ESA and iron costs from observed dose
ranges. RESULTS: Results of the simulation were used to derive a 90% confidence
interval for the potential annual cost savings realized with FC use. Simulations
show a 90% probability that an insurer serving 500 dialysis patients could save
between $389,000 and $829,000 annually with the use of FC. The model was most
sensitive to the number of dialysis sessions per month, health plan size, ESA cost,
and proportion of ESRD patients receiving PBs. CONCLUSIONS: The use of FC over
alternative PBs could create a meaningful cost-offset savings and help reduce the
economic burden of treating patients with ESRD.
PUK16
REDUCED USE OF ERYTHROPOIESIS-STIMULATING AGENTS AND
INTRAVENOUS IRON WITH USE OF THE PHOSPHATE BINDER FERRIC CITRATE:
A FACILITY-LEVEL COST-OFFSET MODEL UNDER THE MEDICARE BUNDLE
Mutell R, Rubin JL, Bond TC, Mayne T
DaVita Clinical Research, Minneapolis, MN, USA
OBJECTIVES: The United States Renal Data System reported that of $2.78 billion
spent on injectable drugs for patients with end-stage renal disease (ESRD) during
2009, $1.89 billion was for erythropoiesis-stimulating agents (ESAs), such as epo-
etin alfa. These costs were reimbursed to dialysis providers under the Medicare
Prospective Payment System, where dialysis payment is bundled with injectable
drugs payment. Oral ferric citrate (FC) is a phosphate binder in clinical develop-
ment for hyperphosphatemia treatment in ESRD patients. Clinical trials demon-
strated that FC lowers patients’ serum phosphorus levels with the added benefit of
increasing patients’ serum ferritin and saturated transferrin (TSAT) levels. In an
observational study analyzing data of a large dialysis provider, similar increases in
ferritin and TSAT in patientswith stable hemoglobinwere associatedwith reduced
doses of intravenous (IV) iron and ESAs. METHODS: We created a facility-level
Medicare cost-offset model that considered annual costs of ESRD treatment for
patients prescribed FC versus other phosphate binder medications (PBs). The
model assumed equal price and efficacy between FC and competitor PBs. Model
inputs included the Medicare average sales price of iron and ESAs, proportion of
ESRD patients on PBs, facility-level cost, and Medicare reimbursement rates with
case-mix adjusters. Margin was calculated as the difference between reimburse-
ment and cost.We assessed the effects of FC use to dialysis providers by comparing
margin for patients on FC versus those taking other PBs. RESULTS: With FC use
versus other PBs, annual facility-level reductions in ESA and IV iron administration
were 9.60% and 11.9%, respectively. These decreases translated to an annual cost
savings of approximately 2.56% of the facility’s total annual bundled Medicare
reimbursement. CONCLUSIONS: A 2% potential cost savings with FC use in pa-
tients taking PBs would be an important opportunity for dialysis providers to re-
duce patients’ treatment costs under Medicare’s Prospective Payment System.
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ECONOMIC BENEFITS OF SLOWING PROGRESS TO END STAGE RENAL DISEASE
(ESRD) IN PATIENTS WITH DIABETES-RELATED CHRONIC KIDNEY DISEASE
(DKD), COMPARED WITH STANDARD OF CARE (SOC)
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OBJECTIVES: DKD is the primary cause of ESRD in the US, with 45% of ESRD
associated with diabetes. A cost-effectiveness model was created to evaluate the
long-term costs and benefits of a therapeutic intervention that slows the progress
to ESRD in DKD patients.METHODS: The model is a Monte Carlo microsimulation
of a semi-Markov structure with a lifetime patient perspective. Kidney disease is
modeled as normal, Stages 1 through 5, and ESRD. Proteinuria is modeled as none,
microalbuminuria, andmacroalbuminuria. Themodel incorporates cardiovascular
disease (CVD) events and mortality along with non-CVD mortality. Modeled costs
are therapy costs, regression-equation supplied annual medical costs, and ESRD
costs. Analyses were performed for diabetic males receiving ACEi or ARB therapy,
age 60, macroalbuminuria, and estimated glomerular filtration rates (eGFR) of 30
(Stage 3/4 breakpoint) and 40 (Stage 3b) mL/min/1.73m2. The intervention was
modeled as a chronic pharmaceutical therapy to be administered through kidney
disease Stage 4. We assume this confers a 28% reduction in annual eGFR degrada-
tion; this is in addition to the base case ARB-attributed reduction in eGFR degrada-
tion. Separate economic analyses were performed for annual intervention costs of
$2500 and $7500. RESULTS: Compared with SOC (i.e., ACEi or ARB treatment), and
respectively in patients at eGFRs of 30 and 40, the intervention increased QALYs
(0.29, 0.51) and life years (0.30, 0.66) and also resulted in fewer patients
reaching ESRD (-74/1,000; -104/1,000). For the intervention cost of $2500, cost sav-
ings were realized for both eGFR cohorts. For the $7,500 cost, cost-per-QALY ICERs
were calculated to be $79,965 for the eGFR 30 and $75,052 for the eGFR 40 cohorts.
CONCLUSIONS: Use of an effective therapeutic intervention to slow progression to
ESRD in high risk DKD patients can result in medical benefits (i.e., ESRD cases
avoided) and can be cost-effective or even cost saving.
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COST-EFFECTIVENESS OF PHARMACOLOGIC TREATMENT OF OVERACTIVE
BLADDER
Malone DC1, Armstrong EP1, Bui C2
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OBJECTIVES: To determine the cost-effectiveness of pharmacologic treatments for
overactive bladder.METHODS:A decisionmodel was constructed based on studies
of effectiveness, adverse consequences, comorbid conditions, and medical costs
for the treatment of overactive bladder. The model was based on a previously
published cost-effectiveness model. The 3 month model classifies patients to 1 of
three states after treatments including: 1) complete continence; 2) treatment fail-
ure; and 3) discontinuation of treatment. Estimates of complete continence were
obtained from trials involving products on the US market as of February 2011.
These products included darifenacin, fesoterodine, oxybutynin immediate release
(IR), oxybutynin extended release (ER), oxybutynin topical gel, oxybutynin trans-
dermal patch, solifenacin, tolterodine IR, tolterodine ER, trospium IR, and trospium
ER. A systematic search of MEDLINE and Embase was conducted to identify rele-
vant studies. Costs were derived from the literature and updated to 2011 values
using themedical components of the consumer price index. Medication costs were
based on wholesale acquisition cost. Probabilistic sensitivity analysis was con-
ducted using a Monte Carlo simulation. RESULTS: A total of 51 studies were iden-
tified, of which 11 studies reported complete continence rates. Complete conti-
nence rates ranged from 19.0% for darifenacin to 51.0% for solifenacin. The lowest
cost treatment was oxybutynin IR ($752 per patient) and the highest cost was
trospium IR ($1,223 per patient). The product with the lowest ICER relative to oxy-
butynin was solifenacin at $1,405 per additional continent patient. The cost-effec-
tiveness acceptability curve indicated oxybutynin IR was most cost-effective with
willingness-to-pay (WTP) values less than $10,000, and solifenacin was most cost-
effective at higher WTP values. CONCLUSIONS: Compared with generic oxybu-
tynin IR, only solifenacinwasmore cost-effective and had an ICER below $1,500 per
successfully treated patient. Only oxybutynin IR and solifenacin had a non-zero
probability of being cost-effective as compared to other therapies.
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INCREMENTAL COST-EFFECTIVENESS OF PHARMACIST-MANAGED
ERYTHROPOIESIS-STIMULATING AGENTS CLINICS FOR NON-DIALYSIS
CHRONIC KIDNEY DISEASE PATIENTS
Aspinall SL1, Smith KJ2, Good CB1, Zhao X3, Stone RA2, Tonnu-mihara IQ4,
Cunningham FE1
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OBJECTIVES: Pharmacists successfully manage patients with anemia and chronic
kidney disease (CKD), but these programs’ cost-effectiveness is unknown. This
analysis examines the cost-effectiveness of pharmacist-managed erythropoiesis-
stimulating agents (ESAs) clinics compared to usual physician-based care in pa-
tients with non-dialysis (ND) CKD. METHODS: A Markov model estimated the in-
cremental cost-effectiveness of pharmacist-managed ESA clinics compared with
usual care in outpatients receiving ESAs for ND-CKD at ten VA Medical Centers
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with pharmacist-managed ESA clinics (n314) and at six sites with usual care only
(n167); outpatients were followed for 6months in 2009.We took a VA perspective
with projections over a five-year time horizon; costs and effectiveness values were
discounted at 3%/yr. Strategy-specific likelihoods of target range hemoglobin val-
ues (10-12 g/dl) were based on study results. Utilities for ND-CKD and ESA-related
adverse events and their likelihood were obtained from the literature. ESA costs
were based on average monthly epoetin and darbepoetin doses per patient during
the study and VA ESA cost data. RESULTS: In the base case analysis, cost and effec-
tivenesswere$12,500and2.096quality-adjusted life-years (QALYs) in thepharmacist-
managed ESA clinics and $15,500 and 2.093 QALYs in usual care; ESA clinics domi-
nated usual care. In one-way sensitivity analyses, ESA clinics no longer dominated if
theirpatients’probabilityofbeing in the target range fell to0.54 (basecase0.71)or if the
mean cost/month of epoetin or darbepoetin in ESA clinics increased to approximately
$360 (base case $211) or $460 (base case $250), respectively.When all parameterswere
varied simultaneously in a probabilistic sensitivity analysis, ESA clinics were favored
80% of the time regardless of willingness-to-pay threshold. CONCLUSIONS: Phar-
macist-managed ESA clinics were less costly and more effective than usual care in
patients receiving ESAs for anemia andND-CKD. Results were robust to variation and
support the use of pharmacist-managed ESA clinics.
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OBJECTIVES: Immunosuppressive agents have affected the incidence of acute re-
jection and early graft survival. The purpose of this study was to evaluate the
cost-utility of sirolimus versus tacrolimus for primary prevention of graft rejection
in renal transplant recipients using the Mexican Institute of Social Security (IMSS)
perspective. METHODS: A Markov model was developed to estimate the cost-ef-
fectiveness of sirolimus versus tacrolimus to prevent graft rejection in adult pa-
tients with end-stage renal disease (ESRD). The model estimates total costs and
QALYs per patient in each prophylaxis group. To extrapolate trial results to lifetime
horizon, the model was extended through one-year Markov cycles. The probabili-
ties of experiencing a graft loss, dialysis, and death were estimated from trial
published data; long-term mortality, acquisition costs, and direct treatment costs
were retrieved using IMSS published sources. Cost utility assessment was ex-
pressed in terms of cost per QALY gained. All costs are presented in 2011US dollars.
Probabilistic sensitivity analyses were carried out to test the robustness of the
results. RESULTS: In comparison to tracolimus, sirolimus improved life expec-
tancy, number of QALYs gained, and reduced incidence of complications. The life-
time overall costs of prevent graft rejection in adult patients with ESRD resulted in
a cost per QALY gained of $5846. Over the lifetime period, sirolimus was esti-
mated to gain 8.18 QALYs per patient compared to 7.33 QALYs for tacrolimus.
Sirolimus is estimated to be cost-saving compared to tacrolimus. Notably, results
suggest that sirolimus has a 78% probability of being dominant over tacrolimus
strategy, with 100% of probability in showing an incremental cost-effectiveness
ratio at or below US$13,000 (1 GDP per capita in Mexico) per QALY gained.
CONCLUSIONS: This analysis suggests that at IMSS, sirolimus in comparison to
tacrolimus for prevention of graft rejection in adults patient with ESRD is likely to
be cost saving alternative.
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COST-EFFECTIVENESS ANALYSIS OF SOLIFENACIN SUCCINATE VERSUS
TROSPIUM CHLORIDE IN THE TREATMENT OF PATIENTS WITH OVERACTIVE
BLADDER IN GERMANY
Hart WM1, Nazir J2
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OBJECTIVES: To carry out a cost-utility analysis comparing initial treatment of
patients with overactive bladder (OAB) with solifenacin 5 mg/day versus either
trospium 20mg twice a day or trospium 60 mg/day from the perspective of the
German National Health Service. METHODS: A decision analytic model with a
three-month cycle was developed to follow a cohort of OAB patients treated with
either solifenacin or trospium during a one-year period. Costs and utilities were
accumulated as patients transitioned through the four cycles in themodel. Some of
the solifenacin patients were titrated from 5mg to 10mg/day at 3 months. Utility
values were obtained from the published literature and pad use was based on a US
resource utilisation study. Adherence rates for individual treatments were derived
from a UK GP database review. The change in themean number of urgency urinary
incontinence episodes/day from after 12 weeks was the main outcome measure.
Baseline effectiveness values for solifenacin and trospium were calculated using
the Poisson distribution. Patients who failed second-line therapy were referred for
a specialist visit. Results were expressed in terms of incremental cost-utility ratios.
RESULTS: Total annual costs for solifenacin, trospium 20mg and trospium 60mg
were 982.28 €, 863.23 € and 880.37 € respectively. Drug use represented 47%, 32%and
33% of total costs and pad use varied between 42% and 55%. Differences between
cumulative utilities were small but favoured solifenacin (0.6887 vs. 0.6828 to
0.6830). The baseline incremental cost-effectiveness ratio ranged from 17,104 € to
20,533 per QALY. CONCLUSIONS: Solifenacin would appear to be cost-effective
with an incremental cost-utility of no more than 21,000 €/QALY. Small differences
in utility between the alternatives, however,means that the results are sensitive to
adjustments in the values of the assigned utilities, effectiveness and discontinua-
tion rates.
URINARY/KIDNEY DISORDERS – Patient-Reported Outcomes & Patient Preference
Studies
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COMPARISON OF UTILITY SCORE AND QUALITY OF LIFE SCORE IN THAI
PATIENT BETWEEN TWICE AND THRICE-WEEKLY HEMODIALYSIS
Thaweethamcharoen T, Vasuvattakul S, Noparatayaporn P
Mahidol University, Bangkok, Thailand
OBJECTIVES: To compare the utility scores and quality of life scores between pa-
tients who have twice and thrice-weekly hemodialysis. METHODS: This was a
cross-sectional analytical study in 5 hemodialysis sites ofNephrologyUnit at Siriraj
Hospital (the largest university hospital in Thailand), Face-to-face interview using
EuroQol questionnaire (EQ-5D), VAS, and KDQOL-36 (consists of 3 kidney disease
subscales and SF-12) was conducted between April 2011 and June 2011, one hun-
dred and fifty-three hemodialysis patients were recruited from the chronic hemo-
dialysis clinic unit. This study compared the difference of hemodialysis times in
weekly to utility scores and quality of life scores of patients by using Independent
Student’s t-test. RESULTS: SF-6D (derived from SF12), EQ-5D (UK and Thai prefer-
ence weight), and VAS between the patients who received twice and thrice-weekly
hemodialysis were not significantly different (p0.05). This is true as well for
Symptom/ problem list, Effects of kidney disease, and burden of Kidney Disease
scores. For SF-12, all of physical and mental domains were not significantly differ-
ent as well as all of utility and kidney disease specific scores were not significantly
associated with hemodialysis times in weekly intervals (all, p0.05).
CONCLUSIONS: These findings implied that thrice-weekly could not reflect the
better quality of life than twice-weekly hemodialysis. There was no significant
difference quality of life from the Symptom/ problem list, Effects of kidney disease,
and burden of Kidney Disease between twice and thrice-weekly hemodialysis as
well as the utility scores from SF-6D, EQ-5D and VAS. Further large cohort study of
utility scores or cost effectiveness analysis between the difference of dialysis fre-
quency at weekly intervals, however, should be conducted.
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OBJECTIVES: Analysis of EQ-5D data often focuses on changes in utility, ignoring
valuable information from other parts of the instrument. Our objective was to
explore how the utility index, EQ-5D profile, and EQ-VAS captured change in clin-
ical trials of Mirabegron, a new treatment for overactive bladder (OAB).METHODS:
Data were pooled from three phase III clinical trials that investigated the efficacy
and safety of mirabegron versus placebo. Tolterodine ER 4mg was included as an
active control in one study: 1) Europe and Australia (placebo,mirabegron 50mg and
100mg, and tolterodine 4mg ER); 2) USA andCanada (Placebo,Mirabegron 50mg and
100mg); and 3) USA, Canada and Europe (Placebo, and Mirabegron 25mg and 50mg.
Data were collected at baseline, week 4, 8 and 12. Analyses were performed on full
analysis and per protocol data sets using UK utilities. Analysis controlled for rele-
vant patient characteristics. Analysis of Covariance identified changes from base-
line at each time point in utilities and EQ-VAS, while Areas Under the Curve (AUC)
were estimated to summarise intertemporal differences in effect. RESULTS: In per
protocol analyses, mirabegron 50mg was superior to tolterodine 4mg in changes
from baseline utilities after 12 weeks (p0.05); similarly, AUC results showed mi-
rabegron 50mg to be superior to tolterodine (p0.05) and to placebo (p0.05). In
both cases, the benefit is already apparent at 4 weeks (p0.05). EQ-VAS more con-
sistently indicated superior outcomes: all three mirabegron doses showed statisti-
cally significant greater effectiveness compared to tolterodine at 12 weeks. Indi-
vidual EQ-5D dimensions and the overall profile showed no significant differences
between study arms. CONCLUSIONS: Despite slight contrasts in results between
the EQ-5D derived utilities and EQ-VAS, mirabegron showed quicker and superior
improvement in HR-QoL compared to tolterodine 4mg ER. Research is required to
address future utilitymeasurements, especially in relation to EQ-5D dimensions in
OAB patients.
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EXAMINING THE ROLE OF CAREGIVER TOWARDS BLOOD TRANSFUSION
DECISIONS AMONG INDIVIDUALS WITH CHRONIC KIDNEY DISEASE
Naim A1, Walls D2, Gollins JR3, Reynolds C4
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OBJECTIVES: Examine role of caregiver in supporting treatment decisions towards
blood transfusions among individuals with chronic kidney disease (CKD) currently
not on dialysis.METHODS: An online survey was conducted in 1Q2011. All respon-
dents were18 years and diagnosed with Cancer by a physician. Participants were
asked about blood transfusion history, presence of anemia, types and roles of
caregivers in assisting with management of their CKD and making health and
treatment decisions towards blood transfusion. RESULTS: Of 416 participants, 59%
(n246)were female; 40% (n165)were65 years. 35% (n144) had stage 4 and 58%
(n240) stage 3 CKD. 54% (n226) were anemic. 43% (n179) had received blood
transfusion, whereas, 57% (n237) had no transfusions. 53% (n220) reported that
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